Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children

Trial Identifier: D5290C00008
Sponsor: AstraZeneca
Collaborator:
IQVIA
NCTID:: NCT04484935
Start Date: September 2020
Primary Completion Date: February 2023
Study Completion Date: February 2023
Condition: Immune, Inflammatory & Infections - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Afrikaans Translation
English (UK) Translation
Spanish Translation
French (Belgium) Translation
Japanese Translation
Dutch (Belgium) Translation
Polish Translation
Russian (Ukraine) Translation
Ukrainian Translation
Southern Sotho Translation
Xhosa Translation
Zulu Translation

Trial Locations

Country Location
BE Bruxelles, BE, 1200
BE Liège, BE, 4000
ES Barcelona, ES, 8035
ES Granada, ES, 18014
ES Madrid, ES, 28041
ES Madrid, ES, 28046
GB Nottingham, GB, NG7 2UH
JP Bunkyo-ku, JP, 113-8519
JP Fuchu-shi, JP, 183-8561
JP Kawasaki-shi, JP, 216-8511
JP Kurume-shi, JP, 830-0011
JP Kyoto-shi, JP, 606-8507
JP Nagasaki-shi, JP, 852-8501
JP Setagaya-ku, JP, 157-8535
JP Tsukuba-shi, JP, 305-8576
JP Yokohama-shi, JP, 232 8555
PL Bydgoszcz, PL, 85-048
UA Dnipro, UA, 49006
UA Kharkiv, UA, 61075
US, CA Los Angeles, CA, US, 90027
US, FL Tampa, FL, US, 33606
US, NY Syracuse, NY, US, 13210
US, SC North Charleston, SC, US, 29406
US, TN Memphis, TN, US, 38105
US, TX Fort Worth, TX, US, 76104
US, WA Tacoma, WA, US, 98405
ZA Parktown, ZA, 2193
ZA Soweto, ZA, 2013